Overview
Urethral cancer is a rare malignancy that originates in the lining (epithelium) of the urethra – the tube that carries urine from the bladder to the outside of the body. It can develop anywhere along the urethra, but most tumors arise in the distal (near the opening) or proximal (near the bladder) segments.
Because the urethra is a small structure, cancers here are often diagnosed at an advanced stage, especially when symptoms are mistaken for common urinary problems.
Who is affected?
- Gender: Men are more frequently affected (≈ 70 % of cases) because the male urethra is longer, providing a larger surface area for malignant transformation.
- Age: The median age at diagnosis is 65 years, though cases have been reported from adolescence to the 90s.
- Geography: Incidence is slightly higher in North America and Europe; worldwide rates are estimated at 1–2 cases per 1 million people per year [1].
Prevalence
Urethral cancer accounts for less than 1 % of all urinary tract cancers and less than 0.02 % of all cancers diagnosed in the United States [2]. Despite its rarity, prompt recognition is crucial because the disease can spread quickly to nearby structures such as the prostate, vagina, or bladder.
Symptoms
Symptoms often mimic benign conditions (e.g., urinary tract infection, prostatitis). A high index of suspicion is needed when they persist or worsen.
- Painful or burning urination (dysuria): A persistent, burning sensation during voiding that does not improve with antibiotics.
- Blood in the urine (hematuria): May appear as pink‑red urine or visible clots. In men, blood can also be seen at the urethral opening.
- Urethral discharge: Clear, mucoid, or purulent drainage that is not linked to infection.
- Urethral narrowing (stricture) leading to weak urinary stream: Difficulty starting or stopping urination, a spraying stream, or feeling of incomplete emptying.
- Painful erection or ejaculation (in men): May indicate involvement of the corpus spongiosum.
- Perineal or genital pain: Aching pain in the area between the scrotum and anus (men) or between the vulva and anus (women).
- Lumps or nodules: Palpable masses on the penis, scrotum, or around the vaginal opening.
- Swelling or redness of the genitalia: Often mistaken for cellulitis.
- Unexplained weight loss, fatigue, or night sweats: Systemic signs that may point to advanced disease.
Causes and Risk Factors
Urethral cancer is usually a result of genetic mutations triggered by chronic irritation, infection, or exposure to carcinogens. The exact cause is unknown in many patients, but several risk factors have been identified.
Established Risk Factors
- Chronic urethral inflammation or infection: Repeated urinary tract infections, sexually transmitted infections (e.g., HPV, gonorrhea), or prolonged catheterization can cause cellular changes.
- Human papillomavirus (HPV): High‑risk HPV types 16 and 18 are linked to squamous cell carcinoma of the urethra, especially in women.
- Urethral strictures: Long‑standing strictures create a nidus for malignant transformation.
- Previous radiation therapy: Pelvic radiation for prostate, bladder, or gynecologic cancers increases risk.
- Chemical exposure: Exposure to aromatic amines (found in dyes, rubber, petroleum products) and arsenic‑containing water has been implicated.
- Smoking: Tobacco smoke contains carcinogens that are excreted in urine, exposing the urethral lining.
- Immunosuppression: Organ transplant recipients or patients with HIV have higher incidence.
Genetic & Familial Factors
While rare, hereditary cancer syndromes such as Lynch syndrome (hereditary non‑polyposis colorectal cancer) can predispose to urothelial cancers, including the urethra.
Diagnosis
Diagnosis involves a combination of patient history, physical examination, imaging, and tissue sampling. Early referral to a urologist experienced in urothelial malignancies is essential.
Step‑by‑step Diagnostic Process
- Physical examination: Inspection of the genitalia for lesions, palpation of the perineum, and digital rectal exam (men) or pelvic exam (women).
- Urine cytology: Microscopic analysis for malignant cells; useful but not definitive.
- Urethroscopy (cystourethroscopy): Direct visualization of the urethral lumen using a thin scope; lesions can be photographed and biopsied.
- Biopsy: The gold‑standard diagnostic test. Either a cold‑cup forceps biopsy during urethroscopy or a trans‑perineal/core biopsy is performed.
- Imaging studies:
- Magnetic Resonance Imaging (MRI): Provides detailed soft‑tissue contrast; helps assess local invasion.
- Computed Tomography (CT) of abdomen/pelvis: Evaluates lymph node involvement and distant metastasis.
- Pelvic ultrasound: Often used as a first‑line tool for evaluating proximal lesions.
- Positron Emission Tomography (PET)/CT: Reserved for staging in high‑risk disease.
- Staging: Based on the American Joint Committee on Cancer (AJCC) TNM system (Tumor size/extent, Node involvement, Metastasis). Stages range from I (confined to urethral epithelium) to IV (spread to distant organs).
Treatment Options
Treatment is individualized according to tumor stage, location, histology (squamous, transitional, adenocarcinoma), patient’s overall health, and personal preferences. Multidisciplinary care—urology, medical oncology, radiation oncology, pathology, and supportive services—is the standard.
Localized Disease (Stage I‑II)
- Surgical excision:
- Partial urethrectomy: Removal of the tumor‑bearing segment while preserving continence and sexual function.
- Complete urethrectomy: Recommended when the tumor involves most of the urethra; may require urinary diversion (e.g., ileal conduit).
- Trans‑perineal or perineal approach: Allows removal of surrounding tissues to achieve negative margins.
- Radiation therapy: External beam radiation (EBRT) or brachytherapy can be used as a primary modality when surgery is not feasible or as adjuvant treatment to reduce recurrence.
- Topical or intraluminal chemotherapy: In select superficial lesions, agents such as mitomycin C or 5‑fluorouracil are instilled into the urethra.
Advanced Disease (Stage III‑IV)
- Radical surgery: May involve cystectomy (removal of bladder) with urinary diversion, pelvic exenteration (removal of multiple organs) for extensive spread.
- Combined modality therapy: Chemoradiation (e.g., cisplatin‑based chemo with EBRT) improves local control in bulky tumors.
- Systemic chemotherapy: Regimens used for urothelial carcinoma (gemcitabine + cisplatin or carboplatin) are commonly employed.
- Immunotherapy: Checkpoint inhibitors (e.g., pembrolizumab, atezolizumab) approved for metastatic urothelial carcinoma may be considered when standard chemo fails.
Supportive and Lifestyle Measures
- Smoking cessation – reduces recurrence risk.
- Optimizing nutrition and maintaining a healthy weight to support healing.
- Pelvic floor physiotherapy to improve continence after surgery.
- Psychological counseling or support groups to address emotional impact.
Living with Urethral Cancer
Adaptation after diagnosis focuses on physical recovery, urinary function, sexual health, and emotional well‑being.
Daily Management Tips
- Urinary hygiene: Keep the genital area clean; avoid harsh soaps that can irritate the urethral opening.
- Fluid intake: Aim for 1.5–2 L of water daily unless fluid restriction is advised by your doctor.
- Monitor for changes: Keep a diary of urinary symptoms, bleeding, or new pains and report any worsening promptly.
- Bladder training: If you have a partial urethrectomy, scheduled voiding may help regain control.
- Sexual health: Discuss erectile function or vaginal lubrication with your urologist; medications, devices, or lubricants can improve comfort.
- Follow‑up schedule: Typically every 3–6 months for the first 2 years, then annually; includes physical exam, imaging, and urine cytology.
- Vaccinations: Stay up‑to‑date with flu, pneumococcal, and HPV vaccines (for eligible patients).
Emotional & Social Support
Living with a rare cancer can feel isolating. Consider:
- Joining rare‑cancer support groups (e.g., Rare Cancer Alliance).
- Talking with a mental‑health professional experienced in oncology.
- Using survivorship care plans to coordinate care among specialists.
Prevention
Because many risk factors are modifiable, prevention strategies focus on reducing irritation and carcinogen exposure.
- Quit smoking: The most impactful single step; resources include quitlines and nicotine‑replacement therapy.
- Safe sexual practices: Use condoms to lower HPV transmission; consider HPV vaccination for eligible adults up to age 45 years.
- Avoid prolonged catheter use: If a catheter is needed, ensure regular changes and strict aseptic technique.
- Prompt treatment of urethral infections: Complete prescribed antibiotic courses and follow up if symptoms recur.
- Occupational safety: Use protective equipment when handling aromatic amines or other known carcinogens.
Complications
If left untreated or if treatment fails, urethral cancer can lead to serious complications:
- Urinary obstruction: May cause hydronephrosis (swelling of kidneys) and renal failure.
- Local invasion: Spread to the prostate, bladder, vagina, or pelvic muscles, making surgery more extensive.
- Metastasis: Common sites include pelvic lymph nodes, lungs, liver, and bone.
- Chronic urinary incontinence: Particularly after radical surgery.
- Sexual dysfunction: Erectile dysfunction in men or dyspareunia in women.
- Psychological impact: Anxiety, depression, and body‑image concerns are prevalent.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
- Sudden inability to urinate (acute urinary retention).
- Severe, worsening pain in the genitals, perineum, or lower abdomen.
- Heavy or clotted bleeding from the urethra that does not stop after 30 minutes.
- Signs of infection with fever > 100.4 °F (38 °C), chills, and rapid heart rate.
- Sudden swelling of the penis, scrotum, or vulva accompanied by pain.
These symptoms may signal a blockage, severe infection, or tumor rupture, all of which require immediate medical attention.
References
- American Cancer Society. Urethral Cancer Statistics. 2024. https://www.cancer.org/cancer/urethral-cancer/about/key-statistics.html
- Mayo Clinic. Urethral Cancer. Updated 2023. https://www.mayoclinic.org/diseases-conditions/urethral-cancer/symptoms-causes/syc-20372390
- National Cancer Institute. Urethral Cancer Treatment (PDQ®)–Health Professional Version. 2024. https://www.cancer.gov/types/urethral/hp/urethral-treatment-pdq
- Cleveland Clinic. Urethral Cancer – Diagnosis and Management. 2023. https://my.clevelandclinic.org/health/diseases/22581-urethral-cancer
- World Health Organization. Human papillomavirus (HPV) and Cancer. 2023. https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cancer
- NIH National Institute of Diabetes and Digestive and Kidney Diseases. Urethral Stricture. 2022. https://www.niddk.nih.gov/health-information/urology/urethral-stricture